TheraRadar
Data updated: May 26, 2026

CEFEPIME HYDROCHLORIDE

Infectious Disease Approved 2007-06-18

CEFEPIME HYDROCHLORIDE is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Pyelonephritis; Skin and Skin Structure Infections; Intra-Abdominal Infection.

Source: FDA Label • CHARTWELL RX

How CEFEPIME HYDROCHLORIDE Works

Cefepime is a bactericidal agent that acts by inhibiting bacterial cell wall synthesis. It exerts its effect by binding to one or more penicillin-binding proteins (PBPs), which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, ultimately leading to cell lysis.

Source: FDA Label
8
Indications
--
Phase 3 Trials
18
Years on Market

Details

Status
Discontinued
First Approved
2007-06-18
Routes
INJECTION
Dosage Forms
INJECTABLE

CEFEPIME HYDROCHLORIDE Approval History

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
65 FDA actions from 2007 to 2024
May 2024 ORIGINAL
Update
Aug 2022 SUPPL
Label · Labeling
Jan 2022 SUPPL
Label · Labeling

What CEFEPIME HYDROCHLORIDE Treats

6 indications

CEFEPIME HYDROCHLORIDE is approved for 6 conditions since its original approval in 2007. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pneumonia
  • Febrile Neutropenia
  • Urinary Tract Infection
  • Pyelonephritis
  • Skin and Skin Structure Infections
  • Intra-Abdominal Infection
Source: FDA Label

CEFEPIME HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFEPIME HYDROCHLORIDE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER
CEFEPIME HYDROCHLORIDE
5 shared
SAMSON MEDCL
CEFEPIME IN PLASTIC CONTAINER
CEFEPIME HYDROCHLORIDE
5 shared
Baxter
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER
CEFEPIME HYDROCHLORIDE
4 shared
B BRAUN
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01484015 IRB00015247 NCI-2011-02422, CCCWFU 02110 Ph 1 completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFEPIME HYDROCHLORIDE FDA Label Details

Indications & Usage

CEFEPIME HYDROCHLORIDE is indicated for the treatment of Pneumonia; Febrile Neutropenia; Urinary Tract Infection; Pyelonephritis; Skin and Skin Structure Infections; Intra-Abdominal Infection.

Looking for the branded version?

CEFEPIME IN PLASTIC CONTAINER

Full clinical data, patents, trials, and competitive landscape for cefepime hydrochloride.

See CEFEPIME IN PLASTIC CONTAINER

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.